First Affiliated Hospital Researcher Yields New Findings on Antineoplastics (Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS).

A recent study conducted at the First Affiliated Hospital analyzed the adverse event profiles of third-generation aromatase inhibitors (AIs) used in the treatment of postmenopausal breast cancer patients with positive hormone receptors. The researchers utilized the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) to investigate the safety of these AIs in the real world. The study found that all three AIs (letrozole, anastrozole, and exemestane) had early failure-type profiles and identified several significant adverse events associated with each AI. The analysis provided valuable information for the safe and rational use of these drugs in clinical practice. [Extracted from the article]